DEA Urges Judge to Give GAO Report “No Weight” in Marijuana Rescheduling Case

The Drug Enforcement Administration (DEA) filed a brief Thursday urging a federal administrative law judge to give no weight to a recent Government Accountability Office (GAO) report identifying deficiencies in federal drug-scheduling procedures.

The filings, dated October 29, were submitted in response to an October 22 order from DEA Chief Administrative Law Judge Derek Julius, who admitted the September 23 GAO report into evidence and invited parties to address its significance to the ongoing rescheduling proceedings.

In its six-page brief, the DEA argues that the report does not undermine the scientific and medical findings supporting the proposal to move marijuana from Schedule I to Schedule III under the Controlled Substances Act.

“The Report is not probative to the instant rescheduling analysis and, as a result, should be given no weight by this Tribunal,” the agency states.

The GAO report found that the DEA and Food and Drug Administration (FDA) lack comprehensive written policies governing several aspects of the drug-scheduling process, including procedures for conducting evaluations, making scheduling recommendations and determining a substance’s potential for abuse relative to other drugs.

However, the DEA argues that the absence of certain written procedures does not invalidate the marijuana-specific analysis conducted by the Department of Health and Human Services (HHS).

According to the agency, the factors used to assess marijuana’s abuse potential were identified in HHS’s 2023 recommendation and the federal government’s May 2024 proposed rule. The DEA maintains that those documents provided interested parties with sufficient information about the government’s analytical approach well before this year’s hearings.

The agency also argues that the GAO report contains no substantive findings undermining HHS’s assessment of marijuana’s currently accepted medical use or dependence risks, two additional considerations relevant to Schedule III classification.

“Because the GAO Report is not probative to the rescheduling recommendation, this Tribunal should give the GAO Report no weight,” the DEA concludes.

Opponents of rescheduling presented a sharply different interpretation in three additional briefs submitted Thursday.

The National Drug & Alcohol Screening Association, DUID Victim Voices and Dr. Kenneth Finn argued in a joint filing that the GAO report deserves decisive consideration because it identifies an absence of written standards governing decisions central to the government’s rescheduling recommendation.

The groups contend that HHS changed its approach to determining whether marijuana has an accepted medical use, replacing a longstanding five-part test with a newer two-part framework during the agency’s review.

They also argue that the government’s evaluation excluded or discounted evidence involving psychiatric conditions, pregnancy-related risks, cardiovascular events and other potential harms.

The filing raises concerns about political and financial influences surrounding the rescheduling process, citing directives from Presidents Joe Biden and Donald Trump, industry lobbying and political spending. The groups explicitly state they are not asking the judge to find that misconduct occurred, but argue that documented procedures are necessary to ensure scheduling decisions are based on evidence rather than outside influence.

“The Government should obtain a new HHS evaluation under the written policy FDA has committed to develop,” the groups argue.

Their brief calls on Julius to recommend rejecting the Schedule III proposal based on the existing record.

Smart Approaches to Marijuana and the states of Idaho, Indiana and Nebraska submitted another joint brief arguing that the absence of standardized procedures allowed HHS to alter its evaluation methods without adequately explaining the changes.

The filing specifically challenges how federal officials compared marijuana’s abuse potential with that of other controlled substances and evaluated potential public-health harms.

“The Tribunal should recommend that marijuana remain in Schedule I,” the groups conclude.

The Tennessee Bureau of Investigation separately argued that the GAO report supports its position that federal officials failed to follow required procedures before proposing rescheduling.

Tennessee’s filing contends that the DEA failed to conduct its own required eight-factor analysis before the proposed rule was issued. It also challenges the authority under which the proposal was published, arguing that the DEA administrator, rather than the attorney general, should have issued it.

Those arguments represent the opposing parties’ legal positions, not findings made by Julius.

The competing briefs follow weeks of procedural disputes over the GAO report. On October 22, Julius denied a request to reopen the hearing for additional discovery and testimony but allowed the report into evidence and authorized supplemental arguments addressing its relevance.

Under the judge’s order, parties have until November 5 to submit responses to the October 29 briefs. The temporary stay of proceedings is scheduled to expire when that briefing period concludes.